{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:45:56Z","timestamp":1791085556810,"version":"4.1.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[1996,7]]},"abstract":"<jats:p>\n            <jats:italic>Background and Purpose<\/jats:italic>\n            In animals, drugs that increase brain amine concentrations influence the rate and degree of recovery from cortical lesions. It is therefore conceivable that antidepressants may influence outcome after ischemic brain injury in humans. We evaluated the effects of the norepinephrine reuptake blocker maprotiline and the serotonin reuptake blocker fluoxetine on the motor\/functional capacities of poststroke patients undergoing physical therapy.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Methods<\/jats:italic>\n            Fifty-two severely disabled hemiplegic subjects were randomly assigned to three treatment groups; during 3 months of physical therapy, patients were treated with placebo, maprotiline (150 mg\/d), or fluoxetine (20 mg\/d). Before and at the end of the observation period, we assessed activities of daily living by the Barthel Index, degree of neurological deficit by a neurological scale for hemiplegic subjects, and depressive symptomatology by the Hamilton Depression Rating Scale.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Results<\/jats:italic>\n            The diverse treatments ameliorated walking and activities of daily living capacities to different extents. The greatest improvements were observed in the fluoxetine-treated group and the lowest in the maprotiline-treated group. Furthermore, fluoxetine yielded a significantly larger number of patients with good recovery compared with maprotiline or placebo. These effects of the drugs were not related to their efficacy in treating depressive symptoms.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Conclusions<\/jats:italic>\n            Fluoxetine may facilitate or, alternatively, maprotiline may hinder recovery in poststroke patients undergoing rehabilitation. The effects of fluoxetine as an adjunct to physical therapy warrant further investigation, since treatment with fluoxetine may result in a better functional outcome from stroke than physical therapy alone.\n          <\/jats:p>","DOI":"10.1161\/01.str.27.7.1211","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T20:08:03Z","timestamp":1308341283000},"page":"1211-1214","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":266,"title":["Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic Patients Undergoing Rehabilitation Therapy"],"prefix":"10.1161","volume":"27","author":[{"given":"M.","family":"Dam","sequence":"first","affiliation":[{"name":"the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Tonin","sequence":"additional","affiliation":[{"name":"the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Boni","sequence":"additional","affiliation":[{"name":"the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pizzolato","sequence":"additional","affiliation":[{"name":"the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Casson","sequence":"additional","affiliation":[{"name":"the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ermani","sequence":"additional","affiliation":[{"name":"the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Freo","sequence":"additional","affiliation":[{"name":"the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Piron","sequence":"additional","affiliation":[{"name":"the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Battistin","sequence":"additional","affiliation":[{"name":"the Department of Neurological and Vision Sciences, University of Verona (M.D.); Department of Neurorehabilitation, Hospital San Camillo, Venice (P.T., A. De B., S.C.); and the Department of Neurology and Psychiatry, University of Padua (G.P., M.E., U.F., L.P., L.B.) (Italy)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_1_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.17.6.3810708"},{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.18.5.3629640"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.2.195"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.2190\/N8VU-6LWU-FLJN-XQKV"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.158.1.83"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.24.7.8322398"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1990.00530070083014"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90356-8"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1986.00520080011011"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.25.6.8202964"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245452"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(84)91437-9"},{"key":"e_1_3_1_13_2","first-page":"1","volume":"4","year":"1992","unstructured":"Sutton RL, Feeney DM. \u03b1-Noradrenergic agonists and antagonists affect recovery and maintenance of beam-walking ability after sensorimotor cortex ablation in the rat. Restor Neurol Neurosci. 1992;4:1-11.","journal-title":"Restor Neurol Neurosci"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(94)90345-X"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002060-199404000-00002"},{"key":"e_1_3_1_16_2","unstructured":"Barker EL Blakely RD. Norepinephrine and serotonin transporters: molecular targets of antidepressant drugs. In: Bloom FE Kupfer DJ eds. Psychopharmacology: The Fourth Generation of Progress. New York NY: Raven Press Publishers; 1995:321-333."},{"key":"e_1_3_1_17_2","unstructured":"Richelson E. Cholinergic transduction. In: Bloom FE Kupfer DJ eds. Psychopharmacology: The Fourth Generation of Progress. New York NY: Raven Press Publishers; 1995:125-134."},{"key":"e_1_3_1_18_2","unstructured":"Brotman AW Falk WE Gelemberg AJ. Pharmacologic treatment of acute depressive subtypes. In: Meltzer HY ed. Psychopharmacology: The Third Generation of Progress. New York NY: Raven Press Publishers; 1987:1031-1040."},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Goldstein LB. Pharmacology of recovery after stroke. Stroke. 1990;21(suppl III):III-139-III-142.","DOI":"10.1161\/01.STR.21.11.1636"},{"key":"e_1_3_1_20_2","unstructured":"Bobath B. Adult Hemiplegia: Evaluation and Treatment. London UK: William and Heinnemann; 1978."},{"key":"e_1_3_1_21_2","first-page":"876","volume":"71","year":"1990","unstructured":"Adams RJ, Meador KJ, Sethi KD, Grotta JC, Thomson DS. Graded neurologic scale for use in acute hemispheric stroke treatment protocols. Stroke. 1990;71:876-880.","journal-title":"Stroke"},{"key":"e_1_3_1_22_2","first-page":"61","volume":"14","year":"1965","unstructured":"Mahoney FI, Barthel DW. Functional evaluation: Barthel Index. Md State Med J. 1965;14:61-65.","journal-title":"Md State Med J"},{"key":"e_1_3_1_23_2","first-page":"58","volume":"23","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry.. 1960;23:58-62.","journal-title":"."},{"key":"e_1_3_1_24_2","unstructured":"Bech P Kastrup M Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand. 1986;73(suppl 326):7-37."},{"key":"e_1_3_1_25_2","unstructured":"Freeman R Bear D Greenberg MS. Behavioral disturbances in cerebrovascular disease. In: Vinken PJ Bruyn GW Klawans HL Toole JF eds. Handbook of Clinical Neurology Vol II (55): Vascular Diseases Part III. Amsterdam Netherlands: Elsevier Science Publishers BV; 1989:137-150."},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410120509"},{"key":"e_1_3_1_27_2","unstructured":"Blackwell B. Newer antidepressant drugs. In: Meltzer HY ed. Psychopharmacology: The Third Generation of Progress. New York NY: Raven Press Publishers; 1987:1041-1049."},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411173312008"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(05)80148-7"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002060-199102000-00003"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.3233\/NRE-1992-2409"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.24.8.8342195"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90635-1"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/neu.480250608"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(92)90163-V"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00191844"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Cazalets JR Sqali-Houssaini Y Clarac F. Activation of the central pattern generators for locomotion by serotonin and excitatory amino acids in neonatal rat. J Physiol (Lond). 1992;4454:187-204.","DOI":"10.1113\/jphysiol.1992.sp019296"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(81)90099-X"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)91489-N"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890140410"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90753-Q"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245579"},{"key":"e_1_3_1_43_2","unstructured":"Nestler EJ Duman RS. Intracellular messenger pathways as mediator of neural plasticity. In: Bloom FE Kupfer DJ eds. Psychopharmacology: The Fourth Generation of Progress. New York NY: Raven Press Publishers; 1995:695-704."},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1979.tb06442.x"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410230117"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.27.7.1211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T22:26:30Z","timestamp":1715552790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.27.7.1211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1996,7]]}},"alternative-id":["10.1161\/01.STR.27.7.1211"],"URL":"https:\/\/doi.org\/10.1161\/01.str.27.7.1211","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,7]]},"assertion":[{"value":"1995-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-03-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}